Live Breaking News & Updates on Metabolic dysfunction associated steatotic liver disease

Stay informed with the latest breaking news from Metabolic dysfunction associated steatotic liver disease on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Metabolic dysfunction associated steatotic liver disease and stay connected to the pulse of your community

Uncontrolled Type 1 Diabetes Linked With MASLD Risk in Pediatric Patients

Previous research links type 2 diabetes and metabolic dysfunction–associated steatotic liver disease (MASLD).

Austria , Switzerland , Germany , United-states , American , Pediatric-gastroenterology , Image-credit , Type-1-diabetes , Masld , Metabolic-dysfunction-associated-steatotic-liver-disease , Uncontrolled-t1d-

#VisualAbstract: Aspirin reduces hepatic fat quantity in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) without Cirrhosis

Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Minute-medicine-inc , Aspirin , Cirrhosis , Liver-disease , Masld , Metabolic-dysfunction-associated-steatotic-liver-disease , Metabolic-dysfunction-associated-steatotic-liver-disease-masld- , Steatosis , Studygraphics ,

NAFLD, Viral Hepatitis Among Liver Diseases Associated With Risk of Incident Cataract

NAFLD, ALD, liver fibrosis and cirrhosis, and recently diagnosed viral hepatitis were all associated with a greater risk of cataract.

United-states , China , American , Xiangjia-zhu , Hospital-of-fudan-university , American-liver-foundation , Fudan-university , United-kingdom-biobank , How-many-people-have-liver , About-your , Nonalcoholic-fatty-liver-disease , Hcv

Looking Better: Digital therapy reduces liver fat in 90 days

Better Therapeutics Inc.’s prescription digital therapeutic (PDT) received U.S. FDA breakthrough device designation for metabolic dysfunction-associated steatohepatitis (MASH), an advanced form of fatty liver disease that increases the risk of cirrhosis, liver failure and liver cancer but has few good treatments available.

Better-therapeutics-inc , Better-therapeutics , Bioworld-medtech , Hepatology , Better-therapeutics-inc- , Prescription-digital-therapeutic , Pdt , Metabolic-dysfunction-associated-liver-disease , Metabolic-dysfunction-associated-steatotic-liver-disease , Masld , Non-alcoholic-fatty-liver-disease

SGLT2 Inhibitors Improve Patient Outcomes in NAFLD, Type 2 Diabetes

The analysis of several oral antidiabetic drugs revealed patients taking SGLT2 inhibitors had more NAFLD regression and fewer adverse liver-related outcomes.

United-states , Seoul , Soult-ukpyolsi , South-korea , American , Korean-national-health-information-database , American-diabetes-association , Seoul-national-university-won-kim , Seoul-national-university , Won-kim , Korean-national-health-information

FDA Grants 510(k) Clearance to Liver Attenuation AI Software HealthFLD

HealthFLD, a fully automated AI software for liver attenuation analysis from CT scans, has received FDA 510(k) clearance for use in the general population.

University-of-wisconsin , Wisconsin , United-states , American , Perry-pickhardt , A-stephen-harrison , Madison-perry-pickhardt , Nanox-health , Drug-administration , Public-health , University-of-wisconsin-carbone-cancer-center , University-of-wisconsin-school-medicine

Stephen Harrison, MD: Promising Phase 3 Data for Resmetirom in NASH, Fibrosis

Stephen Harrison, MD, discusses results from the phase 3 MAESTRO-NASH trial, highlighting resmetirom’s safety and efficacy for NASH resolution and fibrosis improvement.

Stephen-harrison , Pinnacle-clinical-research , Drug-administration , New-england-journal , Madrigal-pharmaceutical-new-drug-application , Nafld , Nonalcoholic-fatty-liver-disease , Nash , Nonalcoholic-steatohepatitis , Metabolic-dysfunction-associated-steatohepatitis , Metabolic-dysfunction-associated-steatotic-liver-disease

Hepatology Month in Review: January 2024

The editorial team’s monthly recap of the top news in hepatology features research emphasizing women’s health in liver disease, a look at some less-recognized health benefits associated with achieving SVR, and promising approaches for preventing and treating hepatic conditions.

West-virginia , United-states , Romania , Tatyana-kushner , National-health , Nutrition-examination-survey , Icahn-school-of-medicine-at-mount-sinai , Greater-focus , Icahn-school , Mount-sinai , Hepatitis-c , Hcv

Women With Alcohol-Related Liver Disease Face Greater Risk of Mortality Than Men

Although there was a greater prevalence of ALD and MetALD among male study participants, females had a greater risk of mortality from both SLD phenotypes, highlighting a potentially greater impact of alcohol consumption on women with liver disease than men.

Susan-cheng , Ann-hepatol , Smidt-heart-institute-at-cedars , National-health , Institute-for-research-on-healthy , Nutrition-examination-survey , Healthy-aging , Smidt-heart-institute , Fatty-liver-disease , Alcohol-related-liver-disease , Masld

Fibrosis Screening May Spark Lifestyle Changes in Individuals at Risk of Liver Disease

Screening for liver fibrosis was associated with sustained improvements in alcohol consumption, diet, weight, and exercise in individuals at risk of ALD and MASLD.

Denmark , Odense , Syddanmark , Linkedin-maria-kjaergaard , Maria-kjaergaard , Odense-university-hospital , Fibrosis , Liver-disease , Alcohol-related-liver-disease , Metabolic-dysfunction-associated-steatotic-liver-disease , Transient-elastography